生化基因 BIIB 深 沪
已收盘 04-02 16:00:00 美东时间
177.34
-6.440
-3.50%
华盛通- 最 高182.23
- 今 开181.46
- 成交量 133.93万股
- 最 低 176.39
- 昨 收 183.78
- 总市值 260.26亿
- 52周最高 202.41
- 市盈率 静 20.18
- 换手率 0.91%
- 52周最低 114.66
- 委 比 53.85%
- 总股本 1.47亿
- 历史最高 468.55
- 量 比 1.00
- 振 幅 3.18%
- 历史最低 61.605
- 每 手 1
- 风险率 24.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
56亿美元！Biogen收购Apellis
（来源：药时代） 预计阅读时间：3分钟 2026年3月31日，Biogen宣布以56亿美元收购Apellis Pharmaceuticals（Nasdaq:A...
04-01 11:52
溢价一倍收购Apellis(APLS.US) 百健(BIIB.US)56亿美元重注免疫学与罕见病赛道
百健公司(BIIB.US)已同意以56亿美元收购Apellis Pharmaceuticals(APLS.US)，此举将扩大其在免疫学和罕见病领域的治疗版图，成为该公司历史上规模最大的收购交易之一。
03-31 21:08
Apellis surges on $5.6B buyout deal with Biogen
Eye drug developer Apellis Pharmaceuticals (APLS) added ~137% in the premarket on Tuesday after the company agreed to be acquired by Biogen (BIIB) for $41 per share in a deal worth $5.6B. The acquisit...
03-31 19:15
Biogen receives FDA approval for high-dose Spinraza regimen
The US FDA has approved a high-dose regimen of Biogen's (BIIB) spinal muscular atrophy treatment Spinraza (nusinersen) consisting of 50 mg/5 mL and 28 mg/5 mL doses. Biogen said that the new regimen a...
03-31 00:07
Biogen and Alteogen ink licensing deal for injectables
Alteogen on Wednesday announced an exclusive license agreement with Biogen (BIIB) to develop subcutaneously delivered biologics leveraging the South Korean pharma's Hybrozyme platform technology. At t...
03-26 00:20
CAMP4 Appoints Michael MacLean to its Board of Directors
CAMP4 Therapeutics announced the appointment of Michael MacLean to its Board of Directors. With over 35 years of financial and operational leadership in biotechnology, MacLean brings extensive experience in growing innovative biotech companies. His expertise will support CAMP4 as it advances its CMP-002 program toward a Phase 1/2 clinical trial for SYNGAP1-related disorder, for which there are currently no approved treatments. MacLean previously ...
03-24 11:00
